Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors

The agents currently approved for use in metastatic renal cell carcinoma (mRCC) can be divided broadly into two categories: (1) vascular endothelial growth factor receptor (VEGFR)-directed therapies or (2) inhibitors of the mammalian target of rapamycin (mTOR). The latter category includes everolimu...

Full description

Bibliographic Details
Main Authors: Sumanta Kumar Pal, Robert A. Figlin
Format: Article
Language:English
Published: SAGE Publishing 2010-01-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.4137/CMO.S1590

Similar Items

Similar Items